Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?

por Gonczi, Lorant, Bessissow, Talat, Lakatos, Peter Laszlo
Publicado 2019

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?

por Strohl, Matthew, Gonczi, Lorant, Kurt, Zsuzsanna, Bessissow, Talat, Lakatos, Peter L
Publicado 2018

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

por Reinglas, Jason, Gonczi, Lorant, Kurt, Zsuzsanna, Bessissow, Talat, Lakatos, Peter L
Publicado 2018

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring

por Albader, Farah, Golovics, Petra Anna, Gonczi, Lorant, Bessissow, Talat, Afif, Waqqas, Lakatos, Peter Laszlo
Publicado 2021

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary

por Lontai, Livia, Kürti, Zsuzsanna, Gonczi, Lorant, Komlódi, Nóra, Balogh, Fruzsina, Iliás, Ákos, Lakatos, Peter L.
Publicado 2023

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review

por Al Khoury, Alex, Balram, Bhairavi, Bessissow, Talat, Afif, Waqqas, Gonczi, Lorant, Abreu, Maria, Lakatos, Peter L.
Publicado 2021

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

por Wetwittayakhlang, Panu, Lontai, Livia, Gonczi, Lorant, Golovics, Petra A., Hahn, Gustavo Drügg, Bessissow, Talat, Lakatos, Peter L.
Publicado 2021

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020

por Wetwittayakhlang, Panu, Gonczi, Lorant, Golovics, Petra A., Kurti, Zsuzsanna, Pandur, Tunde, David, Gyula, Erdelyi, Zsuzsanna, Szita, Istvan, Lakatos, Laszlo, Lakatos, Peter L.
Publicado 2023

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance F...

por Kurti, Zsuzsanna, Ilias, Akos, Gonczi, Lorant, Vegh, Zsuzsanna, Fadgyas-Freyler, Petra, Korponay, Gyula, Golovics, Petra A., Lovasz, Barbara D., Lakatos, Peter L.
Publicado 2018

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

por Gonczi, Lorant, Kurti, Zsuzsanna, Rutka, Mariann, Vegh, Zsuzsanna, Farkas, Klaudia, Lovasz, Barbara D., Golovics, Petra A., Gecse, Krisztina B., Szalay, Balazs, Molnar, Tamas, Lakatos, Peter L.
Publicado 2017

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015

por Golovics, Petra Anna, Verdon, Christine, Wetwittayakhlang, Panu, Filliter, Christopher, Gonczi, Lorant, Hahn, Gustavo Drügg, Wild, Gary E., Afif, Waqqas, Bitton, Alain, Bessissow, Talat, Brassard, Paul, Lakatos, Peter L.
Publicado 2022

Patient and general population values for luminal and perianal fistulising Crohn’s disease health states

por Rencz, Fanni, Stalmeier, Peep F. M., Péntek, Márta, Brodszky, Valentin, Ruzsa, Gábor, Gönczi, Lóránt, Palatka, Károly, Herszényi, László, Schäfer, Eszter, Banai, János, Rutka, Mariann, Gulácsi, László, Lakatos, Peter L.
Publicado 2019

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes

por Nene, Sofia, Gonczi, Lorant, Kurti, Zsuzsanna, Morin, Isabelle, Chavez, Kelly, Verdon, Christine, Reinglas, Jason, Kohen, Rita, Bessissow, Talat, Afif, Waqqas, Wild, Gary, Seidman, Ernest, Bitton, Alain, Lakatos, Peter Laszlo
Publicado 2020